Sumitomo Pharma America Doses First Patient With DSP-3077
MARLBOROUGH, Mass., August 12, 2026 Sumitomo Pharma America, Inc. announced that the first patient has received treatment with DSP-3077...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
MARLBOROUGH, Mass., August 12, 2026 Sumitomo Pharma America, Inc. announced that the first patient has received treatment with DSP-3077...
BURLINGTON, Mass., August 12, 2026 Bone Biologics Corporation announced that its rhNELL-1 protein has achieved a validated shelf life...
Paris, France, April 7, 2026 Phase 2 Success Across Respiratory Indications In a major advancement for respiratory disease therapeutics,...
Boulder, Colorado, USA, April 6, 2026 $33.5M ARPA-H Funding Accelerates Regenerative Pipeline In a major boost to regenerative medicine...
ROSWELL, Ga., Feb. 12, 2026 — StimLabs announced that the U.S. Food and Drug Administration has granted 510(k) clearance...
HERZLIYA, Israel, January 29, 2026 — Regentis Biomaterials Ltd. announced a significant expansion of its U.S. clinical site network...
Warsaw, USA, October 28, 2025 — Zimmer Biomet Holdings, Inc. announced that the FDA has granted Breakthrough Device Designation...
